Compare Alcon AG (ALC) vs SpaceX (SPCX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs SpaceX — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while SpaceX trades at $146.67 (market cap $1.97T). The key difference: SpaceX is far larger — about 60.3× Alcon AG's market cap, and Alcon AG pays a 0.54% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| ALC | SPCX | |
|---|---|---|
Market Cap | $32.69B | $1.97T |
Sector | Health | Technology |
52-Week High | $92.22 | $202.09 |
52-Week Low | $62.02 | $135.00 |
Enterprise Value | $36.28B | $1.98T |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
SPCX trades at $160.42, down 0.86% amid its Nasdaq-100 debut. Technical indicators are neutral, with support at $154 and resistance at $167. The company reported 2025 revenue of $18.67B but a net loss of $4.94B, with negative profit margins and high valuation multiples like P/S of 108.68. Recent news highlights inclusion in the Nasdaq-100 and analyst optimism, though earnings misses and cash burn from heavy investing raise concerns.
Outlook: Strong analyst consensus (100% buy, $240.80 target) reflects long-term growth faith in SpaceX's space economy role. However, persistent losses, high valuations, and execution risks in capital-intensive projects present significant downside. Investors face volatility from earnings uncertainty and competitive pressures, balancing speculative growth potential against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
